{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T10:33:09Z","timestamp":1788604389937,"version":"build-2803163510"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","award":["01EO2102"],"award-info":[{"award-number":["01EO2102"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Optimized drug sequencing is an emerging area of interest in the treatment of ulcerative colitis (UC). Comparative real-world data on treatment response to mirikizumab in a cohort with exposure to multiple biologic agents, particularly tumor necrosis factor (TNF)-na\u00efve versus TNF-treated patients, remain limited. This study evaluated the therapeutic response to mirikizumab treatment in a cohort of patients with UC who were refractory to biologic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Consecutive patients with UC treated with mirikizumab between July 01, 2023, and May 31, 2025, at a tertiary university referral center were retrospectively analyzed. The primary endpoint was 12-week clinical remission. The secondary endpoints included clinical remission and biochemical remission between weeks 24 and 50 and between weeks 60 and 80.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 52 patients. Among them, 17 (32.7%) had previous exposure to \u22653 biologic agents\/small molecules. The 12-week clinical remission rate was 35 of 52 patients (67.3%). There was a significant association between the treatment duration and clinical and biochemical remission. The likelihood of achieving clinical remission was 5.583 times higher after 12 weeks of intravenous mirikizumab treatment (odds ratio [OR] = 5.583, p\u2009=\u20090.002). Anti-TNF pretreatment had a positive effect on biochemical remission (OR = 3.489, p\u2009=\u20090.021). Janus kinase inhibitor pretreatment had a negative effect on clinical remission (OR = 0.19, p\u2009=\u20090.019).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Mirikizumab treatment had good short- and long-term efficacy in patients with UC who previously received biologic therapy. In particular, patients with prior anti-TNF therapies had favorable biochemical remission outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0334897","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T17:27:17Z","timestamp":1761326837000},"page":"e0334897","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sequencing Therapy for Optimal Response in Mirikizumab (STORM)-study: A tertiary referral center study on patients with therapy-refractory ulcerative colitis"],"prefix":"10.1371","volume":"20","author":[{"given":"Alica","family":"Kubesch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4201-0315","authenticated-orcid":true,"given":"Raul","family":"Lande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Leutg\u00f6b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Farrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Dahmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Stratmann-Vollrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Dienethal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian Alexander","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Sprinzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7841-0494","authenticated-orcid":true,"given":"Irina","family":"Blumenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"issue":"7","key":"pone.0334897.ref001","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41573-024-00953-0","article-title":"Navigating the complexities of drug development for inflammatory bowel disease","volume":"23","author":"S Honap","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"22","key":"pone.0334897.ref002","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.3748\/wjg.v30.i22.2902","article-title":"Approach to loss of response to advanced therapies in inflammatory bowel disease","volume":"30","author":"N Vootukuru","year":"2024","journal-title":"World J Gastroenterol"},{"issue":"10401","key":"pone.0334897.ref003","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"C Le Berre","year":"2023","journal-title":"Lancet"},{"key":"pone.0334897.ref004","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3390\/biomedicines11020544","article-title":"Defining the failure of medical therapy for inflammatory bowel disease in the era of advanced therapies: a systematic review","volume":"11","author":"M State","year":"2023","journal-title":"Biomedicines"},{"issue":"5","key":"pone.0334897.ref005","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.3390\/ijms25052789","article-title":"Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease","volume":"25","author":"P Puca","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"5","key":"pone.0334897.ref006","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae192","article-title":"Clinical Outcomes After First-Line Anti- Tumor-Necrosis-Factor Treatment of Patients With Inflammatory Bowel Disease-A Prospective Multicenter Cohort Study","volume":"19","author":"M Zhao","year":"2025","journal-title":"J Crohns Colitis"},{"key":"pone.0334897.ref007","doi-asserted-by":"crossref","first-page":"897936","DOI":"10.3389\/fmed.2022.897936","article-title":"Management of non-response and loss of response to anti-tumor necrosis factor therapy in inflammatory bowel disease","volume":"9","author":"J Marsal","year":"2022","journal-title":"Front Med"},{"issue":"1","key":"pone.0334897.ref008","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"T Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"pone.0334897.ref009","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1055\/a-2271-0994","article-title":"Aktualisierte S3-leitlinie colitis ulcerosa (version 6.2)","volume":"62","author":"T Kucharzik","year":"2024","journal-title":"Z Gastroenterol"},{"issue":"6","key":"pone.0334897.ref010","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","article-title":"Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis","volume":"12","author":"S Singh","year":"2018","journal-title":"J Crohns Colitis"},{"key":"pone.0334897.ref011","doi-asserted-by":"crossref","first-page":"17562848231159452","DOI":"10.1177\/17562848231159452","article-title":"Is there an optimal sequence of biologic therapies for inflammatory bowel disease?","volume":"16","author":"B Bressler","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"pone.0334897.ref012","article-title":"A practical approach to positioning therapies in ulcerative colitis","volume":"8","author":"R Yanofsky","year":"2025","journal-title":"J Can Assoc Gastroenterol"},{"issue":"5","key":"pone.0334897.ref013","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","article-title":"Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease","volume":"68","author":"H Schmitt","year":"2019","journal-title":"Gut"},{"issue":"26","key":"pone.0334897.ref014","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"388","author":"G D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"pone.0334897.ref015","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad212.0014","article-title":"OP14 Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis","volume":"18","author":"A Hart","year":"2024","journal-title":"J Crohn\u2019s Colitis"},{"issue":"7","key":"pone.0334897.ref016","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/ibd\/izae253","article-title":"Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study","volume":"31","author":"BE Sands","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"pone.0334897.ref017","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"RS Walmsley","year":"1998","journal-title":"Gut"},{"issue":"2","key":"pone.0334897.ref018","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.cgh.2022.07.027","article-title":"Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis","volume":"21","author":"PS Dulai","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"pone.0334897.ref019","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG Clinical Guideline Update: Ulcerative Colitis in Adults","volume":"120","author":"DT Rubin","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"pone.0334897.ref020","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1007\/s10620-025-08950-y","article-title":"Mirikizumab in the Treatment of Ulcerative Colitis: Initial Real-World Data in a Population from a Large Tertiary Center","volume":"70","author":"J St-Pierre","year":"2025","journal-title":"Dig Dis Sci"},{"issue":"12","key":"pone.0334897.ref021","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/apt.70140","article-title":"Real-World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study","volume":"61","author":"Y Takagi","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"pone.0334897.ref022","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis","volume":"18","author":"S Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T17:27:21Z","timestamp":1761326841000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334897"}},"subtitle":[],"editor":[{"given":"Vipula Rasanga","family":"Bataduwaarachchi,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0334897","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]}}}